Smith & Nephew bolsters sales force for SUPARTZ
This article was originally published in Clinica
Executive Summary
UK company Smith & Nephew (S&N) is stepping up the US launch of its SUPARTZ joint fluid therapy for the treatment of osteoarthritis of the knee by setting up a team of orthopaedic clinic-based specialists. The specialists will promote the new product, together with the company's 470-strong orthopaedic sales force.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.